Sickle cell anaemia Microalbuminuria Sickle cell nephropathy microalbuminuria angiotensin converting enzyme inhibitor glomerular filtration rate
Conditions
Interventions
Oral Lisinopril at 0.1 mg/kg/day was administered to the intervention group for 3 months,oral Vitamin C at 100 mg/day was administered to the placebo group for 3 months
Active Comparator Drug,Placebo Comparator Drug
Lisinopril,Vitamin C
Sponsors
None listed
Eligibility
Sex/Gender
All
Age
1 Years to 18 Years
Inclusion criteria
Inclusion criteria: Children aged 1-18 years, with SCA and microalbuminuria who were in steady state (defined as the absence of fever, or crisis in the previous four weeks or more in a child who was not on any medication other than routine folic acid and prophylactic antimalarial drug), who were being followed up in the sickle cell clinic at FTHG, and whose caregivers consented to the study
Exclusion criteria
Exclusion criteria: Children who were known to have hypertension, diabetes mellitus, HIV, and urinary tract infection were excluded from the study as these conditions are secondary causes of microalbuminuria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| reduction of microalbuminuria using lisinopril after 3 months of lisinopril administration immunoturbidimetric method | — |
Secondary
| Measure | Time frame |
|---|---|
| progression of glomerular filtration rate 3 months after lisinopril commencement modified Jaffe's reaction | — |
Countries
Nigeria
Contacts
Public ContactRASAKI ALIU
Paediatric nephrology association of Nigeria
Outcome results
None listed